Konstantinos V Voudris1,2, Peter Petropulos3, Panagiotis Karyofillis4, Konstantinos Charitakis5. 1. Department of Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Chicago, IL, USA. Kvoudris@gmail.com. 2. Department of Medicine, Advocate Christ Medical Center, 4440 W 95th Street, Suite 131 NOB, Oak Lawn, IL, 60453, USA. Kvoudris@gmail.com. 3. Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA. 4. Division of Interventional Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. 5. Department of Cardiology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Abstract
PURPOSE OF REVIEW: Transcatheter aortic valve replacement (TAVR) has become an established therapy for patients with symptomatic severe aortic stenosis (AS). As the number of patients referred for TAVR increases, so does the prevalence of untreated obstructive coronary artery disease (CAD) in the population under evaluation. Despite the high prevalence of CAD in patients treated with TAVR, the management strategy of concomitant CAD in these patients remains an area of considerable uncertainty. RECENT FINDINGS: Percutaneous coronary intervention (PCI) in patients with CAD and severe AS has been shown to be feasible and safe. Whether revascularization before, during, or after TAVR is optimal remains a subject of debate. All three approaches represent valid strategies with advantages and disadvantages that need to be carefully weighed on an individual basis. Current expert opinions recommend that PCI should be performed before or at the time of TAVR as long as the risk of the procedure does not outweigh the potential benefits. The results of large clinical trials evaluating the optimal revascularization time are closely awaited.
PURPOSE OF REVIEW: Transcatheter aortic valve replacement (TAVR) has become an established therapy for patients with symptomatic severe aortic stenosis (AS). As the number of patients referred for TAVR increases, so does the prevalence of untreated obstructive coronary artery disease (CAD) in the population under evaluation. Despite the high prevalence of CAD in patients treated with TAVR, the management strategy of concomitant CAD in these patients remains an area of considerable uncertainty. RECENT FINDINGS: Percutaneous coronary intervention (PCI) in patients with CAD and severe AS has been shown to be feasible and safe. Whether revascularization before, during, or after TAVR is optimal remains a subject of debate. All three approaches represent valid strategies with advantages and disadvantages that need to be carefully weighed on an individual basis. Current expert opinions recommend that PCI should be performed before or at the time of TAVR as long as the risk of the procedure does not outweigh the potential benefits. The results of large clinical trials evaluating the optimal revascularization time are closely awaited.
Authors: Yanto Sandy Tjang; Yvonne van Hees; Reiner Körfer; Diederick E Grobbee; Geert J M G van der Heijden Journal: Eur J Cardiothorac Surg Date: 2007-07-19 Impact factor: 4.191
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Todd M Dewey; David L Brown; Morley A Herbert; Dan Culica; Craig R Smith; Martin B Leon; Lars G Svensson; Murat Tuzcu; John G Webb; Alain Cribier; Michael J Mack Journal: Ann Thorac Surg Date: 2010-03 Impact factor: 4.330
Authors: Stephen Ramee; Saif Anwaruddin; Gautam Kumar; Robert N Piana; Vasilis Babaliaros; Tanveer Rab; Lloyd W Klein Journal: JACC Cardiovasc Interv Date: 2016-12-12 Impact factor: 11.195
Authors: Miralem Pasic; Stephan Dreysse; Axel Unbehaun; Semih Buz; Thorsten Drews; Christoph Klein; Giuseppe D'Ancona; Roland Hetzer Journal: Interact Cardiovasc Thorac Surg Date: 2012-01-09
Authors: Lenard Conradi; Moritz Seiffert; Olaf Franzen; Stephan Baldus; Johannes Schirmer; Thomas Meinertz; Hermann Reichenspurner; Hendrik Treede Journal: Clin Res Cardiol Date: 2010-10-21 Impact factor: 5.460
Authors: Nicolas M Van Mieghem; Robert M van der Boon; Elhamula Faqiri; Roberto Diletti; Carl Schultz; Robert-Jan van Geuns; Patrick W Serruys; Arie-Pieter Kappetein; Ron T van Domburg; Peter P de Jaegere Journal: JACC Cardiovasc Interv Date: 2013-07-17 Impact factor: 11.195
Authors: Adam Penkalla; Miralem Pasic; Thorsten Drews; Semih Buz; Stephan Dreysse; Marian Kukucka; Alexander Mladenow; Roland Hetzer; Axel Unbehaun Journal: Eur J Cardiothorac Surg Date: 2014-09-12 Impact factor: 4.191
Authors: F D'Ascenzo; F Conrotto; F Giordana; C Moretti; M D'Amico; S Salizzoni; P Omedè; M La Torre; M Thomas; Z Khawaja; D Hildick-Smith; Gp Ussia; M Barbanti; C Tamburino; John Webb; R B Schnabel; M Seiffert; S Wilde; H Treede; V Gasparetto; M Napodano; G Tarantini; P Presbitero; M Mennuni; M L Rossi; M Gasparini; G Biondi Zoccai; M Lupo; M Rinaldi; F Gaita; S Marra Journal: Int J Cardiol Date: 2013-04-28 Impact factor: 4.164